KLRS

Kalaris Therapeutics, Inc. Common Stock

6.61 USD
-0.38
5.44%
At close Apr 21, 4:00 PM EDT
1 day
-5.44%
5 days
-7.42%
1 month
-39.91%
3 months
-29.53%
6 months
-62.91%
Year to date
-36.14%
1 year
-62.34%
5 years
-98.87%
10 years
-98.87%
 

About: Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.

0
Funds holding %
of 7,419 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

12% less funds holding

Funds holding: 60 [Q3] → 53 (-7) [Q4]

31% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 16

32% less capital invested

Capital invested by funds: $36.3M [Q3] → $24.6M (-$11.7M) [Q4]

35% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 17

Research analyst outlook

We haven’t received any recent analyst ratings for KLRS.

Financial journalist opinion

Charts implemented using Lightweight Charts™